[1]
|
Wojtowicz, J.C., Butovich, I.A., McMahon, A., Hogan, R.N., Itani, K.M., Mancini, R., Molai, M. and Linsenbardt, E. (2014) Time-Dependent Degenerative Transformations in the Lipidome of Chalazia. Experimental Eye Research, 127, 261-269. http://dx.doi.org/10.1016/j.exer.2014.08.008
|
[2]
|
Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J.J., de la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., Alegre, A., de Arriba, F., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., van de Velde, H. and San Miguel, J.F. (2008) Bortezomib plus Melphalan and Prednisone in Elderly Untreated Patients with Multiple Myeloma: Updated Time-to-Events Results and Prognostic Factors for Time to Progression. Haematologica, 93, 560-565. http://dx.doi.org/10.3324/haematol.12106
|
[3]
|
Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Diaz-Mediavilla, J., Lahuerta, J.J., de la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., de Arriba, F., Alegre, A., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., van de Velde, H. and San Miguel, J.F. (2006) Bortezomib plus Melphalan and Prednisone in Elderly Untreated Patients with Multiple Myeloma: Results of a Multicenter Phase 1/2 Study. Blood, 108, 2165-2172. http://dx.doi.org/10.1182/blood-2006-04-019778
|
[4]
|
Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. and Anderson, K.C. (2003) A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine, 348, 2609-2617. http://dx.doi.org/10.1056/NEJMoa030288
|
[5]
|
Richardson, P.G., Briemberg, H., Jagannath, S., Wen, P.Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D.S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S.V., Limentani, S., Alsina, M., Orlowski, R.Z., Najarian, K., Esseltine, D., Anderson, K.C. and Amato, A.A. (2006) Frequency, Characteristics, and Reversibility of Peripheral Neuropathy during Treatment of Advanced Multiple Myeloma with Bortezomib. Journal of Clinical Oncology, 24, 3113-3120. http://dx.doi.org/10.1200/JCO.2005.04.7779
|
[6]
|
Agterof, M.J. and Biesma, D.H. (2005) Images in Clinical Medicine. Bortezomib-Induced Skin Lesions. New England Journal of Medicine, 352, 2534. http://dx.doi.org/10.1056/NEJMicm041166
|
[7]
|
Pour, L., Hajek, R., Zdenek, A., Krejci, M., Krivanova, A. and Vorlicek, J. (2005) Skin Lesions Induced by Bortezomib. Haematologica, 90, ECR44.
|
[8]
|
Min, C.K., Lee, S., Kim, Y.J., Eom, K.S., Lee, J.W., Min, W.S., Kim, C.C., Cho, C.S. and Park, G. (2006) Cutaneous Leucoclastic Vasculitis (LV) Following Bortezomib Therapy in a Myeloma Patient; Association with Pro-Inflammatory Cytokines. European Journal of Haematology, 76, 265-268. http://dx.doi.org/10.1111/j.0902-4441.2005.t01-1-EJH2437.x
|
[9]
|
Truchuelo, M., Bagazgoitia, L., Alcantara, J., Velasco, D. and Carrillo, R. (2012) Sweet-Like Lesions Induced by Bortezomib: A Review of the Literature and a Report of 2 Cases. Actas Dermo-Sifiliograficas, 103, 829-831. http://dx.doi.org/10.1016/j.ad.2012.03.002
|
[10]
|
Wu, K.L., Heule, F., Lam, K. and Sonneveld, P. (2006) Pleomorphic Presentation of Cutaneous Lesions Associated with the Proteasome Inhibitor Bortezomib in Patients with Multiple Myeloma. Journal of the American Academy of Dermatology, 55, 897-900. http://dx.doi.org/10.1016/j.jaad.2006.06.030
|
[11]
|
Patrizi, A., Venturi, M., Dika, E., Maibach, H., Tacchetti, P. and Brandi, G. (2014) Cutaneous Adverse Reactions Linked to Targeted Anticancer Therapies Bortezomib and Lenalidomide for Multiple Myeloma: New Drugs, Old Side Effects. Cutaneous and Ocular Toxicology, 33, 1-6. http://dx.doi.org/10.3109/15569527.2013.787086
|
[12]
|
Grob, S.R., Jakobiec, F.A., Rashid, A. and Yoon, M.K. (2014) Chalazia Associated with Bortezomib Therapy for Multiple Myeloma. Ophthalmology, 121, 1845-1847. http://dx.doi.org/10.1016/j.ophtha.2014.04.021
|
[13]
|
Zhang, K., Wang, S., Malhotra, J., Hassler, J.R., Back, S.H., Wang, G., Chang, L., Xu, W., Miao, H., Leonardi, R., Chen, Y.E., Jackowski, S. and Kaufman, R.J. (2011) The Unfolded Protein Response Transducer IRE1 Alpha Prevents ER Stress-Induced Hepatic Steatosis. EMBO Journal, 30, 1357-1375. http://dx.doi.org/10.1038/emboj.2011.52
|